Relugolix Combination Therapy in Black/African American Women with Symptomatic Uterine Fibroids: LIBERTY Long-Term Extension Study

In the LIBERTY Long-Term Extension study, once-daily relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly improved uterine fibroid-associated heavy menstrual bleeding over the 52-week treatment period in the overall study population.

https://www.ajog.org/article/S0002-9378(23)00760-3/fulltext?rss=yes

Source: American Journal of Obstetrics and Gynecology - October 18, 2023 Category: OBGYN Authors: Elizabeth A. STEWART, Ayman AL-HENDY, Andrea S. LUKES, O. Sandra MADUEKE-LAVEAUX, Emily ZHU, Sarah PROEHL, Thierry SCHULMANN, Erica E. MARSH Tags: Original Research: Gynecology Source Type: research